Literature DB >> 34855082

Role of JNK in the Regulation of Xenobiotic Metabolizing Function of Hepatocytes.

O S Bryushinina1, Yu G Zyuz'kova1, E A Yanovskaya1, N Y Abdrashitova1, G A Frelikh1, A P Lakeev1, D V Tsuran1, V V Udut1, G N Zyuz'kov2.   

Abstract

We studied the role of JNK in the regulation of the metabolism of xenobiotic venlafaxine by liver cells under in vitro conditions. The inhibitory role of this protein kinase in the biotransformation of this psychotropic agent by hepatocytes was demonstrated. JNK inhibitor added to the liver homogenate containing antidepressant enhanced and accelerated the formation of the only pharmacologically active venlafaxine metabolite O-desmethylvenlafaxine in the cell suspension. The results show the promise of studying modifiers of activity of intracellular signaling molecules (in particular, mitogen-activated protein kinases) to develop a fundamentally new approach to control the transformation of xenobiotics and to create a new class of pharmaceutical, target regulators of drugs metabolism.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  JNK; P450; intracellular signal transduction; metabolism; xenobiotics

Mesh：

Substances：

Year:  2021        PMID： 34855082     DOI： 10.1007/s10517-021-05352-8

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  10 in total

1.  Specific Features of Intracellular Signal Transduction in the Regulation of Functions of Neural Stem Cells and Committed Neuronal Progenitors.

Authors:  G N Zyuz'kov; L A Miroshnichenko; T Yu Polyakova; V V Zhdanov; E V Simanina; L A Stavrova; M G Danilets
Journal:  Bull Exp Biol Med       Date:  2021-03-16       Impact factor: 0.804

2.  The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report.

Authors:  Maxim Kuzin; Isabel Scharrer; Daniele Nolan; Markus Baumgartner; Michael Paulzen; Georgios Schoretsanitis; Franziskos Xepapadakos
Journal:  Basic Clin Pharmacol Toxicol       Date:  2020-05-18       Impact factor: 4.080

3.  Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxine.

Authors:  Maike Scherf-Clavel; Leif Hommers; Catherina Wurst; Saskia Stonawski; Jürgen Deckert; Katharina Domschke; Stefan Unterecker; Andreas Menke
Journal:  J Psychopharmacol       Date:  2020-07-16       Impact factor: 4.153

4.  Metabolism and Bioactivation: It's Time to Expect the Unexpected.

Authors:  James P Driscoll; Corinne M Sadlowski; Nina R Shah; Antonio Feula
Journal:  J Med Chem       Date:  2020-04-21       Impact factor: 7.446

5.  Psychopharmacological Effects of JNK Inhibitor in Posthypoxic Encephalopathy and Mechanisms of Their Development.

Authors:  G N Zyuz'kov; N I Suslov; T N Povet'eva; Yu V Nesterova; O G Afanas'eva; E V Udut; L A Miroshnichenko; E V Simanina; T Yu Polyakova; L A Stavrova; A V Chaikovskii; P V Kul'pin; V V Udut; A M Dygai; V V Zhdanov
Journal:  Bull Exp Biol Med       Date:  2017-06-05       Impact factor: 0.804

6.  Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.

Authors:  Chaten D Jessel; Sam Mostafa; Maria Potiriadis; Ian P Everall; Jane M Gunn; Chad A Bousman
Journal:  Pharmacogenet Genomics       Date:  2020-09       Impact factor: 2.089

7.  CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.

Authors:  Taro Sasaki; Norio Yasui-Furukori; Hazuki Komahashi-Sasaki; Masataka Shinozaki; Yuki Hayashi; Kazuko Kato; Yoshimasa Inoue; Shoko Tsuchimine; Takashi Watanabe; Norio Sugawara; Kazutaka Shimoda
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-02-09       Impact factor: 4.080

8.  Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring.

Authors:  T J Stamm; D Becker; L M Sondergeld; K Wiethoff; C Hiemke; G O'Malley; R Ricken; M Bauer; M Adli
Journal:  Pharmacopsychiatry       Date:  2014-07-23       Impact factor: 5.788

9.  Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.

Authors:  Eduardo Tozatto; Jhohann Richard de Lima Benzi; Adriana Rocha; Eduardo Barbosa Coelho; Vera Lucia Lanchote
Journal:  J Clin Pharmacol       Date:  2020-09-24       Impact factor: 3.126
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.